An Audio Review Journal for Surgeons: Bridging the Gap between Research and Patient Care


Interview with Shawna C Willey, MD 

Track 1: Case: A 58-year-old woman with ER/PR-positive ductal carcinoma in situ (DCIS), lobular carcinoma in situ and columnar cell changes desires a good cosmetic outcome in her breasts
Track 2: Role of the DCIS Recurrence Risk Score in patients being considered for radiation therapy (RT)
Track 3: Use of the DCIS Recurrence Risk Score in clinical practice
Track 4: Patient selection for intraoperative RT (IORT)
Track 5: Cosmetic outcomes with IORT
Track 6: Controversy surrounding the efficacy of IORT versus whole-breast irradiation
Track 7: External beam partial-breast irradiation
Track 8 Case: A 57-year-old woman with a 1.5-cm, ER/PR-positive, HER2-positive, node-positive breast cancer receives neoadjuvant chemotherapy, trastuzumab and pertuzumab
Track 9: Axillary node management after neoadjuvant chemotherapy
Track 10: Utility of genomic assays in the neoadjuvant setting
Track 11: Alliance A11202 and NSABP-B-51 Phase III studies of axillary treatment after neoadjuvant chemotherapy for patients with node-positive versus node-negative disease
Track 12: Strategies for high-risk HER2-positive breast cancer: Addition of pertuzumab to adjuvant chemotherapy/trastuzumab and postadjuvant neratinib
Track 13: Case: A 37-year-old woman with B-cup breasts has a 5.5-cm, strongly ER/PR-positive, HER2-negative, node-negative breast cancer and a 21-gene signature Recurrence Score® (RS) of 16
Track 14: Use of genomic assays for patients with node-positive breast cancer
Track 15: Mastectomy and re-excision rates in relation to adoption of a consensus guideline on surgical margins

Interview with Charles E Geyer Jr, MD

Track 1: Case: A 69-year-old woman with a 1-cm, strongly ER-positive, HER2-negative breast cancer has a 2.4-cm positive axillary node
Track 2: Neoadjuvant therapy for patients with node-positive, HER2-positive or triple-negative breast cancer and a tumor size of 2 centimeters or larger
Track 3: Management of the axilla in patients with node-negative or node-positive disease after neoadjuvant therapy
Track 4: Neoadjuvant endocrine therapy for strongly ER-positive breast cancer
Track 5: Use of the 21-gene signature assay to choose neoadjuvant endocrine therapy or chemotherapy for patients with ER-positive breast cancer
Track 6: Use of genomic assays to guide treatment decision-making for patients with ER-positive, HER2-negative breast cancer
Track 7: RxPONDER study of adjuvant endocrine therapy with or without chemotherapy for patients with hormone receptor-positive, HER2-negative invasive breast cancer, 1 to 3 positive nodes and an RS of 25 or lower
Track 8: Overview of breast cancer genomic assays
Track 9: Using genomic assays to predict benefit from extended adjuvant endocrine therapy
 
FACULTY
 
Shawna C Willey, MD
Vice-Chairman of Clinical Affairs
Department of Surgery
MedStar Georgetown
University Hospital
Director, Betty Lou Ourisman
Breast Health Center
Lombardi Comprehensive Cancer Center
Washington, DC
 
Charles E Geyer Jr, MD 
Associate Director of Clinical Research
Massey Cancer Center
Richmond, Virginia
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida